The VALEDA Light Delivery System is the first FDA-approved device for dry age-related macular degeneration (AMD) and the first treatment available for intermediate dry macular degeneration. AMD is a prevalent eye condition that typically affects older adults — it impacts the macula, the central part of the retina responsible for sharp, direct vision and crucial for how we perceive things in front of us. Dry AMD accounts for 80–90% of cases and develops as the macula naturally thins with age and small yellow deposits called drusen build up beneath the retina, gradually breaking down the tissue above and causing slow vision loss. Wet AMD is a rarer form in which abnormal blood vessels develop beneath the retina, leak blood and fluid, and cause faster damage. There is no cure for AMD, but treatments and support options like VALEDA can help slow the progression of vision changes and improve quality of life — an urgent need given that AMD affects roughly 196 million people worldwide today, is projected to reach 288 million by 2040, and accounts for 8.7% of worldwide blindness. VALEDA uses Photobiomodulation (PBM), a therapy that delivers specific multi-wavelength light to the retinal tissues to stimulate cellular activity at the mitochondrial level — boosting cellular function, enhancing metabolic activity, and reducing oxidative stress and inflammation, all major factors in the progression of dry AMD. As the first and only FDA-approved treatment for Dry AMD, VALEDA is non-invasive, painless, safe, and requires no dilation — designed to slow the progression of Dry AMD, improve visual performance, enhance contrast sensitivity, and support healthier retina cells.